Microvascular Complications of Diabetes 7 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MVCD7 MCID: MCR120 MIFTS: 47	Microvascular Complications of Diabetes 7 (MVCD7) Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Microvascular Complications of Diabetes 7

MalaCards integrated aliases for Microvascular Complications of Diabetes 7:

Name: Microvascular Complications of Diabetes 7 ⁵⁷ ⁷³ ¹²

Microvascular Complications of Diabetes, Susceptibility to, 7 ⁵⁷ ²⁸ ⁵

Diabetic Nephropathy ⁷³ ⁷¹

Mvcd7 ⁵⁷ ⁷³

Nonproliferative Retinopathy, Diabetic, Susceptibility to ⁵⁷

Proliferative Retinopathy, Diabetic, Susceptibility to ⁵⁷

Microvascular Complications of Diabetes, Type 7 ³⁸

Nephropathy, Diabetic, Susceptibility to ⁵⁷

Nonproliferative Retinopathy, Diabetic ⁵⁷

Diabetic Non-Proliferative Retinopathy ⁷³

Proliferative Retinopathy, Diabetic ⁵⁷

Proliferative Diabetic Retinopathy ⁷¹

Diabetic Proliferative Retinopathy ⁷³

Nephropathy, Diabetic ⁵⁷

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Nephrological diseases Eye diseases Cardiovascular diseases Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM® ⁵⁷ 612635

OMIM Phenotypic Series ⁵⁷ PS603933

MeSH ⁴³ D048909

MedGen ⁴⁰ C2673520 CN034317

UMLS ⁷¹ C0011881 C0154830

Sources

Summaries for Microvascular Complications of Diabetes 7

UniProtKB/Swiss-Prot: ⁷³ Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary: Microvascular Complications of Diabetes 7, also known as microvascular complications of diabetes, susceptibility to, 7, is related to hemochromatosis, type 1 and transferrin serum level quantitative trait locus 2. An important gene associated with Microvascular Complications of Diabetes 7 is HFE (Homeostatic Iron Regulator). The drugs Pentoxifylline and Captopril have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and pancreas.

More information from OMIM: 612635 PS603933

Sources

Related Diseases for Microvascular Complications of Diabetes 7

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2	Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4	Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6	Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 7 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 558)

#	Related Disease	Score	Top Affiliating Genes
1	hemochromatosis, type 1	29.5	HFE-AS1 HFE
2	transferrin serum level quantitative trait locus 2	29.3	HFE-AS1 HFE
3	cystic fibrosis	29.3	HFE-AS1 HFE
4	porphyria cutanea tarda	29.3	HFE-AS1 HFE
5	variegate porphyria	29.2	HFE-AS1 HFE
6	alzheimer disease, familial, 1	28.9	HFE-AS1 HFE
7	microvascular complications of diabetes 1	11.5
8	microvascular complications of diabetes 2	11.5
9	type 1 diabetes mellitus	11.5
10	microvascular complications of diabetes 3	11.3
11	microvascular complications of diabetes 4	11.3
12	microvascular complications of diabetes 6	11.3
13	diabetic angiopathy	11.2
14	maturity-onset diabetes of the young	11.2
15	hyperglycemia	11.1
16	type 2 diabetes mellitus	11.1
17	renal fibrosis	11.1
18	oto-palatal-digital syndrome	11.0
19	diabetes mellitus	11.0
20	chronic kidney disease	11.0
21	glomerulonephritis	10.8
22	lipid metabolism disorder	10.8
23	nephrotic syndrome	10.7
24	hypertension, essential	10.7
25	rickets	10.7
26	vascular disease	10.7
27	ceroid lipofuscinosis, neuronal, 5	10.6
28	uremia	10.6
29	iga glomerulonephritis	10.6
30	iga nephropathy 1	10.6
31	membranous nephropathy	10.6
32	down syndrome	10.5
33	mckusick-kaufman syndrome	10.5
34	abdominal obesity-metabolic syndrome 1	10.5
35	hypercholesterolemia, familial, 1	10.5
36	cardiovascular system disease	10.5
37	neuropathy	10.5
38	kidney hypertrophy	10.5
39	peripheral vascular disease	10.5
40	glomerular disease	10.5
41	arteriosclerosis	10.5
42	lipoid nephrosis	10.5
43	leptin deficiency or dysfunction	10.5
44	focal segmental glomerulosclerosis	10.5
45	glucose intolerance	10.5
46	hypolipoproteinemia	10.5
47	deficiency anemia	10.5
48	pre-eclampsia	10.5
49	autonomic neuropathy	10.5
50	familial hyperlipidemia	10.5

Comorbidity relations with Microvascular Complications of Diabetes 7 via Phenotypic Disease Network (PDN): (show all 11)

Acute Cystitis	Chronic Kidney Disease
Deficiency Anemia	Diabetic Cataract
Diabetic Polyneuropathy	Heart Disease
Hypertension, Essential	Hypoglycemia
Microvascular Complications of Diabetes 1	Peripheral Vascular Disease
Rubeosis Iridis

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 7:

Sources

Symptoms & Phenotypes for Microvascular Complications of Diabetes 7

Clinical features from OMIM®:

612635 (Updated 08-Dec-2022)

Sources

Drugs & Therapeutics for Microvascular Complications of Diabetes 7

Drugs for Microvascular Complications of Diabetes 7 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 347)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Pentoxifylline

Approved, Investigational

Phase 4

6493-05-6

4740

Captopril

Approved

Phase 4

62571-86-2

44093

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Clopidogrel

Approved

Phase 4

120202-66-6, 113665-84-2

60606

Vildagliptin

Approved, Investigational

Phase 4

274901-16-5

6918537

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Moxonidine

Approved, Investigational

Phase 4

75438-57-2

4810

Mecobalamin

Approved, Investigational

Phase 4

13422-55-4

Hydroxocobalamin

Approved

Phase 4

13422-51-0

15589840 44475014

Alprostadil

Approved, Investigational

Phase 4

745-65-3

5280723

Amlodipine

Approved

Phase 4

88150-42-9

2162

Atenolol

Approved

Phase 4

29122-68-7

2249

Doxazosin

Approved

Phase 4

74191-85-8

3157

Acetylsalicylic acid

Approved, Vet_approved

Phase 4

50-78-2

2244

Irbesartan

Approved, Investigational

Phase 4

138402-11-6

3749

Furosemide

Approved, Vet_approved

Phase 4

54-31-9

3440

Simvastatin

Approved

Phase 4

79902-63-9

54454

Clonidine

Approved

Phase 4

4205-91-8, 4205-90-7

2803 20179

Insulin glulisine

Approved

Phase 4

207748-29-6

Insulin glargine

Approved

Phase 4

160337-95-1

118984454

Lixisenatide

Approved

Phase 4

320367-13-3

90472060 16139342

Glucagon

Approved

Phase 4

16941-32-5

16133228 16186314

Zaleplon

Approved, Illicit, Investigational

Phase 4

151319-34-5

5719

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

6473866 445643

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Carbamide peroxide

Approved

Phase 4

124-43-6

Candesartan cilexetil

Approved

Phase 4

145040-37-5

Allopurinol

Approved

Phase 4

315-30-0

2094 135401907

Nisoldipine

Approved

Phase 4

63675-72-9

4499

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Probucol

Approved, Investigational

Phase 4

23288-49-5

4912

Cilostazol

Approved, Investigational

Phase 4

73963-72-1

2754

Exenatide

Approved, Investigational

Phase 4

141758-74-9

45588096

Atorvastatin

Approved

Phase 4

134523-00-5

60823

Indapamide

Approved

Phase 4

26807-65-8

3702

Insulin lispro

Approved

Phase 4

133107-64-9

16132438

Metformin

Approved

Phase 4

1115-70-4, 657-24-9

4091

Verapamil

Approved

Phase 4

152-11-4, 52-53-9

2520

Trandolapril

Approved

Phase 4

87679-37-6

5484727

Saxagliptin

Approved

Phase 4

361442-04-8

11243969

Dipivefrin

Approved

Phase 4

52365-63-6

3105

Enalaprilat

Approved

Phase 4

76420-72-9

6917719 5462501

Enalapril

Approved, Vet_approved

Phase 4

75847-73-3

40466924 5388962 5362032

Ertugliflozin

Approved, Investigational

Phase 4

1210344-57-2

75075340 44814423

Perindopril

Approved

Phase 4

82834-16-0, 107133-36-8

107807

Ranibizumab

Approved

Phase 4

347396-82-1

Grape

Approved

Phase 4

Bevacizumab

Approved, Investigational

Phase 4

216974-75-3

135329020

Interventional clinical trials:

(show top 50) (show all 462)

#	Name	Status	NCT ID	Phase	Drugs
1	Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes: a Prospective Interventional Study	Unknown status	NCT04127084	Phase 4	SGLT2 Inhibition
2	Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy.	Unknown status	NCT00870402	Phase 4	Spironolactone;Placebo
3	Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy	Unknown status	NCT01673204	Phase 4	Calcitriol;Placebo
4	Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy	Unknown status	NCT01300273	Phase 4
5	A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy	Unknown status	NCT01743014	Phase 4	Ramipril;Clopidogrel
6	Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients	Unknown status	NCT01316068	Phase 4	intravenous use of sulodexide followed by oral use;use of sulodexide orally only
7	Prevention of Renal Complications of Diabetes With Thiamine	Unknown status	NCT01725412	Phase 4
8	Comparative Effecacy of Metformin and Vildagliptin on Cardiometabolic Risk Factors, Metabolic Syndrome, and Diabetic Nephropathy Progression	Unknown status	NCT04485845	Phase 4	Vildagliptin;Captopril Tablets;MetFORMIN 500 Mg Oral Tablet
9	Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy	Unknown status	NCT03664414	Phase 4	pentoxifylline
10	Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy	Unknown status	NCT01094769	Phase 4	Moxonidine;Placebo
11	Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy	Unknown status	NCT01921192	Phase 4	Folic Acid, vit B6 and B12;Placebo
12	Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment.	Unknown status	NCT00563628	Phase 4
13	Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment.	Unknown status	NCT00563043	Phase 4
14	Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy.	Unknown status	NCT02005432	Phase 4	Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
15	Prospective, Single-blind, Randomised, Controlled, Multi-centre Study to Evaluate the Benefit of Ranibizumab as an Adjunctive Therapy to Vitrectomy for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Oedema	Unknown status	NCT04464694	Phase 4	Ranibizumab
16	A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase	Unknown status	NCT01486771	Phase 4	Macugen ® (pegaptanib sodium)
17	Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT)	Unknown status	NCT03506750	Phase 4	IVC
18	Efficacy of Calcium Dobesilate in Treating Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy (CALM-DR): a Single-blind, Multicenter, Cluster-randomized, Controlled Trial	Unknown status	NCT04283162	Phase 4	Calcium Dobesilate
19	Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters	Unknown status	NCT01023698	Phase 4
20	Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy	Unknown status	NCT01824043	Phase 4	intravitreal ranibizumab injections
21	A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study -	Completed	NCT00153088	Phase 4	Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
22	Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients	Completed	NCT02628106	Phase 4	Lipo-PGE1
23	Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events.	Completed	NCT00535925	Phase 4	SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
24	Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)	Completed	NCT00708981	Phase 4
25	A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus	Completed	NCT02276196	Phase 4	Lixisenatide;Insulin glulisine
26	Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus	Completed	NCT00419835	Phase 4	enalapril;losartan
27	FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients	Completed	NCT01703234	Phase 4	Ramipril
28	Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes	Completed	NCT01869881	Phase 4	Anplag(Sarpogrelate);Placebo
29	Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria	Completed	NCT00893425	Phase 4	ramipril
30	A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy	Completed	NCT00573430	Phase 4	Candesartan Cilexetil;Candesartan Cilexetil 32mg
31	Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up	Completed	NCT00171574	Phase 4	Valsartan;Valsartan plus HCTZ;Lisinopril
32	A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan	Completed	NCT03147677	Phase 4	Alfacalcidol;Irbesartan
33	Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial	Completed	NCT02502071	Phase 4	sodium bicarbonate
34	A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy	Completed	NCT00565318	Phase 4	Benfotiamine;Placebo
35	A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria	Completed	NCT02829177	Phase 4	Allopurinol;Placebo
36	A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy	Completed	NCT00363987	Phase 4	Ketosteril®
37	Spironolactone in Diabetic Nephropathy	Completed	NCT00317954	Phase 4	Spironolactone
38	Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy	Completed	NCT00311870	Phase 4	nisoldipine;lisinopril
39	Randomized Open Label Study Comparing the Metabolic Control of Kidney Transplant Recipients With Type 2 Diabetes Receiving Either Prograf or Neoral as Part of a ATG Induction, Prednisone Free and Monitored MMF Immunosuppressive Regimen.	Completed	NCT00296296	Phase 4	Cyclosporin;Tacrolimus
40	Effect of Continuous Positive Airway Pressure on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea	Completed	NCT02816762	Phase 4	Pharmacological treatment
41	"Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study"	Completed	NCT01028287	Phase 4	ACTH
42	A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy	Completed	NCT01252056	Phase 4	Probucol;Probucol and Cilostazol
43	Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria	Completed	NCT01588795	Phase 4	Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
44	The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy	Completed	NCT01331317	Phase 4	Paricalcitol
45	Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes	Completed	NCT02914691	Phase 4	Dapagliflozine 10 mg once daily tablet treatment;Placebo identical once daily tablet treatment
46	Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study	Completed	NCT02690883	Phase 4	Exenatide;Lispro
47	A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese	Completed	NCT00272831	Phase 4	Cilostazol;Placebo
48	Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy	Completed	NCT00295555	Phase 4	Effects of doxazosin on morning surge in diabetic patients
49	Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy	Completed	NCT00276133	Phase 4	Effects of atorvastatin versus probucol on small dense LDL
50	A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)	Completed	NCT00235014	Phase 4	trandolapril;trandolapril/verapamil;placebo;verapamil

Search NIH Clinical Center for Microvascular Complications of Diabetes 7

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

benazepril

Benazepril hydrochloride

candesartan

candesartan cilexetil

Captopril

Enalapril

Enalapril Maleate

Enalaprilat

eprosartan

Eprosartan mesylate

Fosinopril

Fosinopril Sodium

irbesartan

Lisinopril

Losartan

Losartan Potassium

moexipril

Moexipril hydrochloride

olmesartan

Olmesartan medoxomil

Perindopril

Perindopril arginine

Perindopril Erbumine

quinapril

Quinapril hydrochloride

Ramipril

telmisartan

trandolapril

valsartan

Sources

Genetic Tests for Microvascular Complications of Diabetes 7

Genetic tests related to Microvascular Complications of Diabetes 7:

#	Genetic test	Affiliating Genes
1	Microvascular Complications of Diabetes, Susceptibility to, 7 ²⁸	HFE

Sources

Anatomical Context for Microvascular Complications of Diabetes 7

Organs/tissues related to Microvascular Complications of Diabetes 7:

MalaCards : Kidney, Endothelial, Pancreas, Retina, Eye, Bone Marrow, Heart

Sources

Publications for Microvascular Complications of Diabetes 7

Articles related to Microvascular Complications of Diabetes 7:

(show top 50) (show all 21059)

#	Title	Authors	PMID	Year
1	The HFE gene is associated to an earlier age of onset and to the presence of diabetic nephropathy in diabetes mellitus type 2. ⁶² ⁵⁷ ⁵	Oliva R...Gomis R	15347835	2004
2	Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. ⁶² ⁵⁷ ⁵	Moczulski DK...Gawlik B	11423500	2001
3	Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study. ⁵⁷ ⁵	Davis TM...Bruce DG	18566337	2008
4	A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes. ⁵⁷ ⁵	Peterlin B...Petrovic D	14618419	2003
5	Proliferative retinopathy in a patient with diabetes mellitus and idiopathic haemochromatosis. ⁵⁷ ⁵	Walsh CH...Malins JM	678784	1978
6	Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. ⁵	Benyamin B...Visscher PM	19084217	2009
7	Iron-overload-related disease in HFE hereditary hemochromatosis. ⁵	Rienhoff HY	18504828	2008
8	Iron-overload-related disease in HFE hereditary hemochromatosis. ⁵	Waalen J...Beutler E	18499578	2008
9	Frequency of the hemochromatosis gene mutations in the population of Serbia and Montenegro. ⁵	Saric M...Romac S	16879202	2006
10	Association of porphyria cutanea tarda with hereditary hemochromatosis. ⁵	Mehrany K...Pittelkow MR	15280838	2004
11	Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. ⁵	Robson KJ...Smith AD	15060098	2004
12	Hemochromatosis mutations in the general population: iron overload progression rate. ⁵	Andersen RV...Nordestgaard BG	15070663	2004
13	The 16189 variant of mitochondrial DNA occurs more frequently in C282Y homozygotes with haemochromatosis than those without iron loading. ⁵	Livesey KJ...Robson KJ	14729817	2004
14	Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. ⁵	Tomatsu S...Sly WS	14673107	2003
15	Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. ⁵	Merryweather-Clarke AT...Robson KJ	12915468	2003
16	Hereditary haemochromatosis: only 1% of adult HFEC282Y homozygotes in South Wales have a clinical diagnosis of iron overload. ⁵	McCune CA...Worwood M	12436244	2002
17	The hemochromatosis protein HFE inhibits iron export from macrophages. ⁵	Drakesmith H...Townsend AR	12429850	2002
18	Clinical haemochromatosis in HFE mutation carriers. ⁵	Poullis A...Maxwell JD	12241803	2002
19	Co-selection of the H63D mutation and the HLA-A29 allele: a new paradigm of linkage disequilibrium? ⁵	Cardoso CS...Porto G	11904676	2002
20	Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. ⁵	Beutler E...Gelbart T	11812557	2002
21	Identification of an endogenous RNA transcribed from the antisense strand of the HFE gene. ⁵	Thenie AC...Mosser J	11532995	2001
22	Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause? ⁵	Aguilar-Martinez P...Larrey D	11358905	2001
23	Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. ⁵	Jeffrey GP...Adams PC	10431233	1999
24	Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. ⁵	de Villiers JN...Kotze MJ	10401000	1999
25	The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. ⁵	Levy JE...Andrews NC	10381492	1999
26	Celtic origin of the C282Y mutation of hemochromatosis. ⁵	Lucotte G	9851897	1998
27	Hemochromatosis in Ireland and HFE. ⁵	Ryan E...Crowe J	9851896	1998
28	The hemochromatosis 845 G-->A and 187 C-->G mutations: prevalence in non-Caucasian populations. ⁵	Cullen LM...Jazwinska EC	9585606	1998
29	Targeted disruption of the HFE gene. ⁵	Beutler E	9482831	1998
30	Phenotype-genotype correlation in haemochromatosis subjects. ⁵	Mura C...Ferec C	9439654	1997
31	Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. ⁵	Waheed A...Sly WS	9356458	1997
32	A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. ⁵	Jouanolle AM...David V	9341868	1997
33	The significance of the 187G (H63D) mutation in hemochromatosis. ⁵	Beutler E	9326341	1997
34	Homozygosity for the predominant Cys282Tyr mutation and absence of disease expression in hereditary haemochromatosis. ⁵	Rhodes DA...Trowsdale J	9321765	1997
35	The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. ⁵	Feder JN...Schatzman RC	9162021	1997
36	Global prevalence of putative haemochromatosis mutations. ⁵	Merryweather-Clarke AT...Robson KJ	9138148	1997
37	Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. ⁵	Carella M...Camaschella C	9106528	1997
38	Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. ⁵	Roberts AG...Elder GH	9024376	1997
39	Absence of the hemochromatosis gene Cys282Tyr mutation in three ethnic groups from Algeria (Mzab), Ethiopia, and Senegal. ⁵	Roth M...Coppin H	9211748	1997
40	Haemochromatosis and HLA-H. ⁵	Jouanolle AM...David V	8896550	1996
41	Haemochromatosis and HLA-H. ⁵	Jazwinska EC...Walsh TP	8896549	1996
42	A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. ⁵	Feder JN...Wolff RK	8696333	1996
43	Ginsenoside Rg1 attenuates glomerular fibrosis by inhibiting CD36/TRPC6/NFAT2 signaling in type 2 diabetes mellitus mice. ⁶²	Han Y...Li W	36375645	2023
44	Network pharmacology analysis combined with experimental validation to explore the therapeutic mechanism of Schisandra Chinensis Mixture on diabetic nephropathy. ⁶²	Ma Y...Zhang M	36280016	2023
45	Beneficial effects of ginsenosides on diabetic nephropathy: A systematical review and meta-analysis of preclinical evidence. ⁶²	Chen XM...Tang D	36341813	2023
46	Suppression of lncRNA Snhg1 inhibits high glucose-induced inflammation and proliferation in mouse mesangial cells. ⁶²	Sheng J...Wu B	36243327	2023
47	The changing trajectory of diabetic kidney disease. ⁶²	Mistry N...Bakris GL	36250469	2023
48	Interplay between long non-coding RNA MALAT1 and pyroptosis in diabetic nephropathy patients. ⁶²	Shoeib HM...El-Dardiry SA	36270460	2023
49	Ion channels and channelopathies in glomeruli. ⁶²	Staruschenko A...Dryer SE	36007181	2023
50	Modern indications for referral for kidney and pancreas transplantation. ⁶²	Fridell JA...Stratta RJ	36444661	2023

Sources

Genes for Microvascular Complications of Diabetes 7

Genes related to Microvascular Complications of Diabetes 7 (2 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	HFE	Homeostatic Iron Regulator	Protein Coding	1083.14	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ Risk factor ⁵ GeneCards inferred via : Disorders (show sections)	678784 8696333 8896549 (more) 8896550 9024376 9106528 9138148 9162021 9211748 9321765 9326341 9341868 9356458 9439654 9482831 9585606 9851896 9851897 10381492 10401000 10431233 11358905 11423500 11532995 11812557 11904676 12241803 12429850 12436244 12915468 14618419 14673107 14729817 15060098 15070663 15280838 15347835 16879202 18499578 18504828 18566337 19084217
2	HFE-AS1	HFE Antisense RNA 1	RNA Gene	425	Pathogenic ⁵ Risk factor ⁵	12429850 8696333 8896550 (more) 11532995 11812557 9106528 11358905 11904676 14673107 11423500 15347835 18566337

Sources

Variations for Microvascular Complications of Diabetes 7

ClinVar genetic disease variations for Microvascular Complications of Diabetes 7:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	HFE-AS1, HFE	NM_000410.4(HFE):c.187C>G (p.His63Asp)	SNV	Pathogenic Risk Factor	10	rs1799945	GRCh37: 6:26091179-26091179 GRCh38: 6:26090951-26090951
2	HFE	NM_000410.4(HFE):c.845G>A (p.Cys282Tyr)	SNV	Risk Factor	9	rs1800562	GRCh37: 6:26093141-26093141 GRCh38: 6:26092913-26092913
3	HFE-AS1, HFE	NM_000410.4(HFE):c.193A>T (p.Ser65Cys)	SNV	Uncertain Significance	11	rs1800730	GRCh37: 6:26091185-26091185 GRCh38: 6:26090957-26090957